Earnings Feed
Start Free
Home/Filings/4/0001209191-18-038661
4//SEC Filing

Pontifax (Israel) III, L.P. 4

Accession 0001209191-18-038661

CIK 0001035354other
View on SEC.govCompany Profile

Filed

Jun 18, 8:00 PM ET

Accepted

Jun 19, 6:22 PM ET

Size

14.6 KB

Accession

0001209191-18-038661

Insider Transaction Report

Form 4
Period: 2018-06-15
Eloxx Pharmaceuticals, Inc.ELOX
Pontifax (Cayman) III, L.P.
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
Pontifax (Israel) III, L.P.
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
Pontifax Management III G.P. (2011) Ltd.
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
Pontifax Management Fund III L.P.
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-06-15+40,000→ 40,000 total(indirect: See Footnote)
    Exercise: $23.27Exp: 2028-06-15→ Common Stock (40,000 underlying)
Footnotes (3)
  • [F1]One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
  • [F2]The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management III G.P. (2011) Ltd. ("Pontifax 3"). Mr. Kariv will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
  • [F3]The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 3. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.

Documents

1 file

Issuer

Eloxx Pharmaceuticals, Inc.

CIK 0001035354

→
Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001726038

Filing Metadata

Form type
4
Filed
Jun 18, 8:00 PM ET
Accepted
Jun 19, 6:22 PM ET
Size
14.6 KB
View on SEC.gov